Cargando…

TOX as a potential target for immunotherapy in lymphocytic malignancies

TOX (thymocyte selection-associated HMG BOX) is a member of a family of transcriptional factors that contain the highly conserved high mobility group box (HMG-box) region. Increasing studies have shown that TOX is involved in maintaining tumors and promoting T cell exhaustion. In this review, we sum...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liang, Chaofeng, Huang, Shuxin, Zhao, Yujie, Chen, Shaohua, Li, Yangqiu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7981945/ https://www.ncbi.nlm.nih.gov/pubmed/33743809 http://dx.doi.org/10.1186/s40364-021-00275-y

Ejemplares similares

Higher TOX Genes Expression Is Associated With Poor Overall Survival for Patients With Acute Myeloid Leukemia
por: Liang, Chaofeng, et al.
Publicado: (2021)

Increased TOX expression associates with exhausted T cells in patients with multiple myeloma
por: Zhao, Yujie, et al.
Publicado: (2022)

The role of A20 in the pathogenesis of lymphocytic malignancy
por: Zhang, Fan, et al.
Publicado: (2012)

The role of PD-1 and PD-L1 in T-cell immune suppression in patients with hematological malignancies
por: Shi, Li, et al.
Publicado: (2013)

TOX regulates T lymphocytes differentiation and its function in tumor
por: Niu, Haiyue, et al.
Publicado: (2023)

Targeting LAG-3, TIM-3, and TIGIT for cancer immunotherapy
por: Cai, Letong, et al.
Publicado: (2023)

Different expression patterns of VISTA concurrent with PD-1, Tim-3, and TIGIT on T cell subsets in peripheral blood and bone marrow from patients with multiple myeloma
por: Huang, Shuxin, et al.
Publicado: (2022)

The role of peptide and DNA vaccines in myeloid leukemia immunotherapy
por: Lin, Chen, et al.
Publicado: (2013)

Atomistic Analysis of ToxN and ToxI Complex Unbinding Mechanism
por: Hu, Guodong, et al.
Publicado: (2018)

T cell receptor-engineered T cells for leukemia immunotherapy
por: Zhang, Yikai, et al.
Publicado: (2019)

The role of BCL11B in hematological malignancy
por: Huang, Xin, et al.
Publicado: (2012)

New insights into antigen specific immunotherapy for chronic myeloid leukemia
por: Li, Yangqiu, et al.
Publicado: (2012)

On the Utility of ToxCast™ and ToxPi as Methods for Identifying New Obesogens
por: Janesick, Amanda Shaine, et al.
Publicado: (2016)

Targeting T cell malignancies using CAR-based immunotherapy: challenges and potential solutions
por: Fleischer, Lauren C., et al.
Publicado: (2019)

The periplasmic domains of Vibriocholerae ToxR and ToxS are forming a strong heterodimeric complex independent on the redox state of ToxR cysteines
por: Gubensäk, Nina, et al.
Publicado: (2021)

TCR engineered T cells for solid tumor immunotherapy
por: Zhang, Yikai, et al.
Publicado: (2022)

Comment on “On the Utility of ToxCast™ and ToxPi as Methods for Identifying New Obesogens”
por: Houck, Keith A., et al.
Publicado: (2017)

The complexity of ToxT-dependent transcription in Vibrio cholerae
por: Weber, Gregor G., et al.
Publicado: (2011)

The Role of TOX in the Development of Innate Lymphoid Cells
por: Seehus, Corey R., et al.
Publicado: (2015)

Evolution of T-cell clonality in a patient with Ph-negative acute lymphocytic leukemia occurring after interferon and imatinib therapy for Ph-positive chronic myeloid leukemia
por: Wang, Liang, et al.
Publicado: (2010)

Informing Selection of Nanomaterial Concentrations for ToxCast in Vitro Testing Based on Occupational Exposure Potential
por: Gangwal, Sumit, et al.
Publicado: (2011)

Reply to “Comment on ‘On the Utility of ToxCast™ and ToxPi as Methods for Identifying New Obesogens’”
por: Janesick, Amanda S., et al.
Publicado: (2017)

Potential of ToxCast Data in the Safety Assessment of Food Chemicals
por: Punt, Ans, et al.
Publicado: (2020)

Immunotherapies targeting stimulatory pathways and beyond
por: Marin-Acevedo, Julian A., et al.
Publicado: (2021)

Clinical Case—Rhus Tox
por: Potter, H. E.
Publicado: (1889)

Correction: Targeting LAG-3, TIM-3, and TIGIT for cancer immunotherapy
por: Cai, Letong, et al.
Publicado: (2023)

Potential Immunotherapy Targets for Liver-Directed Therapies, and the Current Scope of Immunotherapeutics for Liver-Related Malignancies
por: Charles, Jonathan, et al.
Publicado: (2023)

Biomarker-guided targeted and immunotherapies in malignant pleural mesothelioma
por: Yang, Haitang, et al.
Publicado: (2020)

T cell senescence and CAR-T cell exhaustion in hematological malignancies
por: Kasakovski, Dimitri, et al.
Publicado: (2018)

TOX3 is a favorable prognostic indicator and potential immunomodulatory factor in lung adenocarcinoma
por: Zeng, De, et al.
Publicado: (2019)

Expression patterns of immune checkpoints in acute myeloid leukemia
por: Chen, Cunte, et al.
Publicado: (2020)

Cancer neoantigens as potential targets for immunotherapy
por: Ma, Weijie, et al.
Publicado: (2021)

Inroads to Predict in Vivo Toxicology—An Introduction to the eTOX Project
por: Briggs, Katharine, et al.
Publicado: (2012)

Revisiting the therapeutic potential of homeopathic medicine Rhus Tox for herpes simplex virus and inflammatory conditions
por: Shinde, Mohini D., et al.
Publicado: (2023)

Characterizing Virulence of the Pyrenophora tritici-repentis Isolates Lacking Both ToxA and ToxB Genes
por: Guo, Jingwei, et al.
Publicado: (2018)

Targeting cytotoxic T lymphocytes for cancer immunotherapy
por: Maher, J, et al.
Publicado: (2004)

TOX3 Mutations in Breast Cancer
por: Jones, James Owain, et al.
Publicado: (2013)

TRPs in Tox: Involvement of Transient Receptor Potential-Channels in Chemical-Induced Organ Toxicity—A Structured Review
por: Steinritz, Dirk, et al.
Publicado: (2018)

Potential Mitochondrial Toxicants: Tox21 Screen Identifies Structures of Interest
por: Potera, Carol
Publicado: (2015)

Beyond the Bench: Tox-in-a-Box
por: Freeman, Kris
Publicado: (2005)

Cannot write session to /tmp/vufind_sessions/sess_45aur86ef12lshtajl83p58saf